CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in Northern Chinese population

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Sun, Liang ^a   Meng, Yunxiao ^b   Xie, Yanchen ^c   Zhang, Hua ^d   Zhang, Zheng ^e   Wang, Xiaoxia ^a   Jiang, Bin ^c   Li, Wei ^d   Li, Yao ^c   Yang, Ze ^a  

^a Ministry of Health   (China)

^b TSINGHUA UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d BEIJING HOSPITAL   (China)

^e NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CTLA4 PROTEIN, HUMAN;

ADULT; ARTICLE; CHINESE; COMORBIDITY; CONTROLLED STUDY; CTLA4 GENE; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; ONSET AGE; RISK ASSESSMENT; SEROPREVALENCE; SEX DIFFERENCE; THYMOMA; ADOLESCENT; CHINA; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADOLESCENT; ADULT; CHINA; CTLA-4 ANTIGEN; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; POLYMORPHISM, SINGLE NUCLEOTIDE; ROC CURVE; YOUNG ADULT;

EID: 84903886501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101986     Document Type: Article

References (53)

1. Drachman DB (1994) Myasthenia gravis. N Engl J Med 330: 1797-1810.
2. Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37: 141-149.
3. Aarli JA (1999) Late-onset myasthenia gravis: a changing scene. Arch Neurol 56: 25-27.
4. Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8: 475-490.
5. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1998) Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975. Neurology 51: 933 and 936 pages following.
6. Maniaol AH, Elsais A, Lorentzen AR, Owe JF, Viken MK, et al. (2012) Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 7: e36603.
7. Oosterhuis HJ (1981) Myasthenia gravis. A survey. Clin Neurol Neurosurg 83: 105-135.
8. Nagvekar N, Moody AM, Moss P, Roxanis I, Curnow J, et al. (1998) A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 101: 2268-2277.
9. Reinhardt C, Melms A (2000) Normalization of elevated CD4-/CD8- (double-negative) T cells after thymectomy parallels clinical remission in myasthenia gravis associated with thymic hyperplasia but not thymoma. Ann Neurol 48: 603-608.
10. Rioux JD, Goyette P, Vyse TJ, Hammarstrom L, Fernando MM, et al. (2009) Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A 106: 18680-18685.
11. Kristiansen OP, Larsen ZM, Pociot F (2000) CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity? Genes Immun 1: 170-184.
12. Ueda H, Howson JM, Esposito L, Heward J, Snook H, et al. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511.
13. Teft WA, Kirchhof MG, Madrenas J (2006) A molecular perspective of CTLA-4 function. Annu Rev Immunol 24: 65-97.
14. Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, et al. (2000) CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 165: 1352-1356.
15. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, et al. (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
16. Lee YH, Harley JB, Nath SK (2005) CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Hum Genet 116: 361-367.
17. Sallakci N, Bacanli A, Coskun M, Yavuzer U, Alpsoy E, et al. (2005) CTLA-4 gene 49A/G polymorphism in Turkish patients with Behcet's disease. Clin Exp Dermatol 30: 546-550.
18. Nithiyananthan R, Heward JM, Allahabadia A, Franklyn JA, Gough SC (2002) Polymorphism of the CTLA-4 gene is associated with autoimmune hypothyroidism in the United Kingdom. Thyroid 12: 3-6.
19. Simmonds MJ, Gough SC (2004) Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond. Clin Exp Immunol 136: 1-10.
20. Chang MC, Chang YT, Tien YW, Liang PC, Jan IS, et al. (2007) T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clin Chem 53: 1700-1705.
21. Gu LQ, Zhu W, Zhao SX, Zhao L, Zhang MJ, et al. (2010) Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease. Clin Endocrinol (Oxf) 72: 248-255.
22. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J (2001) CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2: 145-152.
23. Wang XB, Pirskanen R, Giscombe R, Lefvert AK (2008) Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med 263: 61-69.
24. Chuang WY, Strobel P, Gold R, Nix W, Schalke B, et al. (2005) A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 58: 644-648.
25. Sun L, Yang Z, Jin F, Zhu XQ, Qu YC, et al. (2006) The Gly482Ser variant of the PPARGC1 gene is associated with Type 2 diabetes mellitus in northern Chinese, especially men. Diabet Med 23: 1085-1092.
26. Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22: 1928-1929.
27. Purcell S, Cherny SS, Sham PC (2003) Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19: 149-150.
28. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O (1999) The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 97: 182-190.
29. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ (1995) CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 80: 41-45.
30. Kotsa K, Watson PF, Weetman AP (1997) A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin Endocrinol (Oxf) 46: 551-554.
31. Awata T, Kurihara S, Iitaka M, Takei S, Inoue I, et al. (1998) Association of CTLA-4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin-depleted IDDM as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in the Japanese population. Diabetes 47: 128-129.
32. Waterman EA, Watson PF, Lazarus JH, Parkes AB, Darke C, et al. (1998) A study of the association between a polymorphism in the CTLA-4 gene and postpartum thyroiditis. Clin Endocrinol (Oxf) 49: 251-255.
33. Kemp EH, Ajjan RA, Husebye ES, Peterson P, Uibo R, et al. (1998) A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients. Clin Endocrinol (Oxf) 49: 609-613.
34. Donner H, Seidl C, Braun J, Siegmund T, Herwig J, et al. (1998) CTLA4 gene haplotypes cannot protect from IDDM in the presence of high-risk HLA DQ8 or DQ2 alleles in German families. Diabetes 47: 1158-1160.
35. Nistico L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, et al. (1996) The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 5: 1075-1080.
36. Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Garcia-Lozano JR, et al. (1999) CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis. Tissue Antigens 53: 296-300.
37. Chuang WY, Strobel P, Bohlender-Willke AL, Rieckmann P, Nix W, et al. (2013) Late-onset myasthenia gravis - CTLA4 genotype association and low-forage thymic output of naive T cells. J Autoimmun.
38. Tang H, Quertermous T, Rodriguez B, Kardia SL, Zhu X, et al. (2005) Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 76: 268-275.
39. Chiu HC, Vincent A, Newsom-Davis J, Hsieh KH, Hung T (1987) Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology 37: 1854-1857.
40. Kawaguchi N, Kuwabara S, Nemoto Y, Fukutake T, Satomura Y, et al. (2004) Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000. J Neurol Sci 224: 43-47.
41. Shinomiya N, Nomura Y, Segawa M (2004) A variant of childhood-onset myasthenia gravis: HLA typing and clinical characteristics in Japan. Clin Immunol 110: 154-158.
42. Chen WH, Chiu HC, Hseih RP (1993) Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese. J Neurol Neurosurg Psychiatry 56: 382-385.
43. Matsuki K, Juji T, Tokunaga K, Takamizawa M, Maeda H, et al. (1990) HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 86: 392-399.
44. Zhang X, Yang M, Xu J, Zhang M, Lang B, et al. (2007) Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 78: 386-390.
45. Ngo ST, Steyn FJ, McCombe PA (2014) Gender differences in autoimmune disease. Front Neuroendocrinol.
46. Poulas K, Tzartos SJ (2001) The gender gap in autoimmune disease. Lancet 357: 234.
47. Huang D, Liu L, Noren K, Xia SQ, Trifunovic J, et al. (1998) Genetic association of Ctla-4 to myasthenia gravis with thymoma. J Neuroimmunol 88: 192-198.
48. Wang XB, Kakoulidou M, Qiu Q, Giscombe R, Huang D, et al. (2002) CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis. Genes Immun 3: 46-49.
49. Scuderi F, Marino M, Colonna L, Mannella F, Evoli A, et al. (2002) Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 82: 1139-1146.
50. Anjos S, Nguyen A, Ounissi-Benkalha H, Tessier MC, Polychronakos C (2002) A common autoimmunity predisposing signal peptide variant of the cytotoxic Tlymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 277: 46478-46486.
51. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, et al. (2002) A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation. Immunogenetics 54: 1-8.
52. Quintero-Ronderos P, Montoya-Ortiz G (2012) Epigenetics and autoimmune diseases. Autoimmune Dis 2012: 593720.
53. Zhang P, Su Y, Lu Q (2012) Epigenetics and psoriasis. J Eur Acad Dermatol Venereol 26: 399-403.